The objective of the current effort was to determine the efficacy of Fe(II)-montmorillonite (Fe(II)-MMT)
Introduction
Hyperphosphatemia is a precursor to secondary hyperparathyroidism 1−3 and soft tissue and vascular calcification in chronic kidney disease (CKD), which increases the independent risk factors of chronic kidney disease patients in the incidence of cardiovascular diseases, morbidity, mortality, and hospitalization rates. 4−6 Metaanalysis has shown that the risk for mortality and cardiovascular death increased 18% and 10%, 7 respectively, when blood phosphorus increased by 0.323 mmol/L CKD. Hyperphosphatemia causes vascular calcification and increases the incidence of reactive oxygen species that obstruction proper endothelial function. In addition, hyperphosphatemia increases parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) and inhibits the synthesis of dihydroxy vitamin D3, leading to cardiac vascular disease (CVD) complications.
NKF-K/DOQI guidelines recommend a target for blood phosphorus in CKD patients after dialysis of 1.13-1.78 mmol/L, but clinical success rates are not promising. 8, 9 DOPPS studies have shown that the prevalence of hyperphosphatemia in hemodialysis patients was 57.4% and the prevalence of hyperphosphatemia in peritoneal dialysis patients was 47.7%, while the success rate of blood phosphorus control was only 38.5%. 10 The main treatment for hyperphosphatemia was food intake control 11, 12 and reduction of the intestinal absorption of phosphorus and blood dialysis using a phosphate binder. Excessive diet, however, leads to insufficient protein intake, while regular dialysis treatment for phosphorus removal is limited. Therefore, more than 90% of dialysis patients must control their blood phosphorus 13 within the SBR759 group better than of the sevelamer hydrochloride group; both calcium concentrations were unchanged, adverse reactions and the incidence of serious adverse events were similar, but the overall drug withdrawal rate of the SBR759 group was lower than that of the sevelamer hydrochloride group.
In addition, chronic renal failure patients have inadequate intake or excessive loss of iron. Moreover, an absolute or relative deficiency in erythropoietin (EPO) can cause renal anemia. 22, 23 Anemia can lead to heightened incidences of cardiovascular 24−26 events in patients with CKD and reduce their quality of life.
DOPPS studies suggested that in cases where hemoglobin was administered to patients receiving hemodialysis (hemoglobin, Hb), the mortality and hospitalization rates decreased 10% and 12%, respectively. In recent years, phosphate binders containing iron, such as SBR759 and PA21-1, have entered clinical trials with distinct curative effects.
27,28
Recently, much effort has been devoted to applications of montmorillonite (MMT) in biological fields, especially drug delivery systems. 29−31 According to the previous reports, MMT is a biocompatible material. We tested the effects of Fe(II)-montmorillonite on adenine-induced chronic renal failure in rats with hyperphosphatemia 32 and obtained satisfactory results. In addition, since MMT is a common ingredient in pharmaceutical products, it is also capable of blood compatibility. 33, 34 Fe(II)-montmorillonites are a new type of biocompatible phosphate binder that are able to dissociate free iron and montmorillonite in vivo. Iron bonding with phosphate forms insoluble substances that are excreted, while dissociated montmorillonite is not absorbed and thus can be tuned to achieve a therapeutic aim for high phosphorus. Simultaneously, any excess iron from the montmorillonite solution that did not combine with phosphate can be absorbed to supplement the iron losses found in chronic renal failure patients.
The present study studied the adsorption of phosphate by Fe(II)-MMT under different adsorption conditions including time, pH, and initial phosphate concentration. It should be noted that the concentration of the Fe(II) measured by UV-vis spectrophotometer under all experimental condition was 80 mg/L after several measurements. 32 A possible binding phenomenological construct of MMT that includes Fe(II) and phosphate is presented in Figure 1 . Live experiments were carried out by detecting P (mol L −1 ), red blood cells (RBC), Hb, red blood cell specific volume (HCT), EPO, single positive (SP), and albumin (ALB) in male golden hamsters. 
Results and discussion

Effect of time on the adsorption of phosphate
The experiments were carried out to optimize the time required for maximum adsorption of phosphate onto Fe(II)-MMT. Figure 2 shows the effect of time on the adsorption of phosphate. The adsorption rate (the slope) of phosphate was high within 90 min, indicating that the adsorption greatly increased. At 140 min, the adsorption no longer increased, indicating that the equilibrium adsorption was being approached. Therefore, the adsorption time was set to 140 min to achieve maximum adsorption efficiency. The capacity of phosphate adsorption at equilibrium was calculated from the following equation:
where q e (mg/g) is the phosphate species adsorbed at equilibrium, C 0 (mg/L) is the initial solution concentration of phosphate, C e (mg/L) is the equilibrium concentration of phosphate in solution, V (L) is the volume of aqueous solutions containing phosphate, and m (g) is the mass of Fe(II)-montmorillonites.
Effect of pH on the adsorption of phosphate
To determine the effect of pH on adsorption capacity, pH levels ranging from 1 to 10 were prepared. Phosphate and Fe(II)-MMT systems were treated at different pH at constant temperature (37 • C), time (140 min), and concentration (40 mg/g). As shown in Figure 3 , the adsorption capacities were similar except for at pH 3.0, at which it was 3.7 mg/g. Fe(II)-MMT can allow Fe(II) and MMT to leach, while the leached Fe(II) can combine with phosphate to form an insoluble precipitate and serve to remove phosphate. With an increase in pH, Fe(II) can be oxidized and cannot combine with phosphate; thus, the adsorption capacity decreased. The pH value should be appropriate in the human body. The pH value is too high or too low, which are not conducive to the release of Fe(II) ion. It is known that Fe(II) ion would be hydrolyzed at pH < 2.0; on the other hand, Fe(II) ion may be complexed at pH > 10. It was thus found that the maximum adsorption was at pH 3.0.
Effect of initial phosphate concentration on its adsorption onto Fe(II)-MMT
To achieve maximum adsorption, the experiments were performed at different initial concentrations of phosphate at constant temperature (37 • C), time (140 min), and pH (3.0). As shown in Figure 4 , as the initial concentration of phosphate in the solution increased, the amount of adsorption increased, a phenomenon ascribed to a greater concentration gradient at the onset. However, it reached equilibrium when the initial phosphate concentration was at 60 mg/L while the maximum adsorption capacity was 5.75 mg of phosphate/g of Fe(II)-MMT. 
Analyses of adsorption isotherms
The experiments were carried out to determine the adsorbent concentration of phosphate onto Fe(II)-MMT. 
where q e (mg/g) is the amount adsorbed at equilibrium, q m (mg/g) is the maximum monolayer adsorption 
where q e (mg/g) is the amount adsorbed at equilibrium, K F [mg/g(L/mg)1/n] and n is the empirical parameter related to the adsorption capacity and intensity adsorption, and C e (mg/L) is the equilibrium concentration of the phosphate buffer solution. The linear plot of ln q e versus ln C e can give K F and n. The fitted constants of the Langmuir and Freundlich models are shown in Table 1 . Figure 6 . The characteristic 2 θ peak of the (001) 
X-ray diffraction analysis
XRD patterns of Fe(II)-MMT and Fe(II)-MMT with adsorbed phosphate are illustrated in
Raman spectroscopy analysis
Raman spectroscopy can be used to analyze chemical and structural changes at the micrometer scale level (1 µ m) on the surface. 37 As shown in Figure 7 , the band at 306 cm 
Zeta potential
Analyses of live experiments
The live experiments had three groups: normal control group (n = 10), adenine-induced chronic renal failure model group (n = 10), and adenine-induced chronic renal failure with added Fe(II)-MMT treatment group (n = 10). The normal control group was gavaged using 2 mL/120 g water daily, the model group was gavaged using 0.5% adenine 2 mL/120 g daily, and the treatment group was gavaged using 0.5% adenine 2 mL/120 g and then 300 mg/kg Fe(II)-montmorillonites after 2 weeks. The above animals were continuously gavaged for 6 weeks, after which blood sampling from the sixth week was done to detect P (mol L −1 ) RBC (10 10 ), Hb (g/L), HCT (%), EPO (mu/mL), SP (g/L), and ALB (g/L). The results are shown in Tables 2 and 3 . Table 3 . The RBC, Hb, HCT, EPO, SP, and ALB test results of chronic renal failure anemia. Fe(II)-montmorillonites reduce the blood phosphorus of hyperphosphatemia rats, thereby reducing the occurrence of hyperphosphatemia. In Table 3 , Fe(II)-montmorillonites show room for improvement in the decline of chronic renal failure anemia model RBC, Hb, and HCT caused by adenine. Meanwhile there is also room for improvement for EPO, SP, and ALB.
Experimental
Materials
Montmorillonites with a cation-exchange capacity (CEC) of 80 mmol/100 g were obtained from Shandong SiBang Pharmaceutical Co., Ltd. The chemical composition of the montmorillonites was determined by X-ray fluorescence spectroscopy:
, with a loss on ignition of 7.41%. The preparation of Fe(II)-MMT sample has already been described. 32 Thirty healthy male golden hamsters weighing 120 g ± 20 g were provided by the Experimental Animal Center of Shandong University. All chemicals used were analytical reagent grade and obtained from Aladdin Reagent (China). N 2 -gas was used for adsorption. All pH in the experiments was measured with a pHS-3C acidity meter.
Adsorption experiments
The adsorption experiments were conducted to optimize the time required for maximum adsorption of phosphate onto Fe(II)-MMT. First 200 mL of aqueous solution of phosphate containing 13.1 mg of sodium dihydrogen phosphate and 6.6 mg of ascorbic acid were mixed with 100 mg of Fe(II)-MMT powder for 10, 20, 30, 40, 70, 90, 140, 190, 240 , and 290 min at 37
• C in a 250-mL conical flask with constant temperature oscillation. The mixtures were centrifuged and then the concentration of phosphate in the supernatant was determined by UV-vis spectroscopy at λ max = 700 nm. Similarly, the experiments were carried out to determine the optimum pH and maximum adsorption of phosphate onto Fe(II)-MMT at pH of 1, 2, 3, 4, 5, 6, 7, 8, 9 , and 10 and the initial amounts were 9.9, 11.5, 13.1, 14.8, 16.4, 18.1, 19.7, 21.4, 23 , and 26.3 mg, respectively. All the experimental data were repeated three times and the relative errors ranged within ±3%.
Characterization of materials
The total amounts of phosphate in solutions were determined by T6 UV-vis spectrophotometer (PGENERAL)
at 700 nm equipped with a quartz cell having a path length of 1 cm. X-ray diffraction (XRD) patterns were obtained on a Bruker D8 Advance diffraction analyzer, using Cu Kα radiation. XRD data was obtained in the 2 θ range from 3
• to 10
• . Raman spectra were recorded on a NEXUS 670 spectrograph at a resolution = 0.09 cm −1 and laser wavelength = 633 nm. The zeta potential measurements were carried out using the JS94H micro electrophoresis apparatus. Fe(II)-MMT and Fe(II)-MMT-P suspensions (0.5 g L −1 ) were prepared by dispersing the samples (0.05 g) in distilled water (100 mL). pH of the suspension was raised to ∼ 2 with HCl and the zeta potential measurement was carried out. The pH was slightly increased with NaOH and a new measurement was performed. 41 This procedure was continued until the pH was around 10.0.
Live experiments
The treatment with Fe(II)-montmorillonites for chronic renal failure hyperphosphatemia is as follows:
Thirty male golden hamsters weighing 120 g ± 20 g were randomized into 3 groups with 10 per group.
(1) Normal control group: After fully nourishing the mice for 2 weeks and using 2 mL/120 g water to gavage daily.
(2) Model control group: gavage using 0.5% adenine 2 mL/120 g daily.
(3) Treatment group: gavage using 0.5% adenine 2 mL/120 g, then gavage with 300 mg/kg Fe(II)-montmorillonites after 2 weeks.
The above animals were continuously gavaged for 6 weeks, after which blood sampling was done from the sixth week to detect P (mol L −1 ).
The treatment with Fe(II)-montmorillonites for anemia caused by chronic renal failure is as follows:
Thirty healthy male golden hamsters weighing 120 g ± 20 g were randomized into 3 groups with 10 in each.
(1) Normal control group: After fully nourishing the mice over 2 weeks, 2 mL/120 g water was used to gavage daily.
The above animals were continuously gavaged over 6 weeks, after which blood sampling was done from the sixth week to detect RBC, Hb, HCT, EPO, SP, and ALB.
Conclusions
The adsorption of phosphate onto Fe(II)-MMT attained equilibrium within 140 min. It was thus found that the maximum adsorption was at pH 3.0. In addition, it reached equilibrium when the initial phosphate concentration was at 60 mg/L while the maximum adsorption capacity was 5.75 mg of phosphate/g of Fe(II)-MMT.
Experimental parameters such as time, pH, and initial concentration were investigated and optimized. The optimum condition of the study is that the maximum amount of phosphate adsorption onto Fe(II)-MMT was 5.75 mg/g within 140 min at pH 3.0 and 37
• C. Adsorption isotherms showed that the Langmuir model was better than the Freundlich model. This means that the adsorption of the phosphate on Fe(II)-montmorillonites was monolayer adsorption, and the phosphate was successfully adsorbed either onto the surface or intercalated within interlayer volume. and anemia arising from chronic renal failure. These studies serve to support the notion that Fe(II)-MMT may be a promising drug delivery system for the treatment of chronic renal failure. In the future, more chronic renal failure patients will get timely treatment. There is no doubt that it will play a great role in promoting for the medical profession.
